Compare · FRMM vs NVO
FRMM vs NVO
Side-by-side comparison of Forum Markets Incorporated (FRMM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRMM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, FRMM is down 44.5% and NVO is down 34.2% - NVO leads by 10.2 points.
- FRMM has been more active in the news (12 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for FRMM).
- Company
- Forum Markets Incorporated
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- -
- $220.35B
- 1M return
- +63.21%
- +13.32%
- 1Y return
- -44.48%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 12
- 5
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FRMM
- Forum Markets Incorporated filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form RW filed by Forum Markets Incorporated
- Forum Markets Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Forum Board Reinitiates Share Repurchase Program; Forms Special Committee of Independent Directors to Evaluate Proposals to Maximize Shareholder Value
- SEC Form EFFECT filed by Forum Markets Incorporated
- Forum Markets Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by Forum Markets Incorporated
- Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Forum Announces Initiation of Analyst Coverage by Benchmark
- The Benchmark Company initiated coverage on Forum Markets with a new price target
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S